CZ300368B6 - Zpusob výroby rapamycinového derivátu - Google Patents

Zpusob výroby rapamycinového derivátu Download PDF

Info

Publication number
CZ300368B6
CZ300368B6 CZ20021136A CZ20021136A CZ300368B6 CZ 300368 B6 CZ300368 B6 CZ 300368B6 CZ 20021136 A CZ20021136 A CZ 20021136A CZ 20021136 A CZ20021136 A CZ 20021136A CZ 300368 B6 CZ300368 B6 CZ 300368B6
Authority
CZ
Czechia
Prior art keywords
acid
rapamycin
process according
ether
alkyl
Prior art date
Application number
CZ20021136A
Other languages
Czech (cs)
English (en)
Other versions
CZ20021136A3 (cs
Inventor
Shaw@Chia-Cheng
Hamilton Sellstedt@John
Noureldin@Razzak
Karen Cheal@Gloria
Fortier@Genevieve
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of CZ20021136A3 publication Critical patent/CZ20021136A3/cs
Publication of CZ300368B6 publication Critical patent/CZ300368B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ20021136A 1999-09-29 2000-09-27 Zpusob výroby rapamycinového derivátu CZ300368B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40883099A 1999-09-29 1999-09-29

Publications (2)

Publication Number Publication Date
CZ20021136A3 CZ20021136A3 (cs) 2002-06-12
CZ300368B6 true CZ300368B6 (cs) 2009-05-06

Family

ID=23617953

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20021136A CZ300368B6 (cs) 1999-09-29 2000-09-27 Zpusob výroby rapamycinového derivátu

Country Status (24)

Country Link
EP (1) EP1216251B1 (enExample)
JP (1) JP4289813B2 (enExample)
KR (1) KR100754236B1 (enExample)
CN (1) CN1176925C (enExample)
AR (1) AR029181A1 (enExample)
AT (1) ATE233269T1 (enExample)
AU (1) AU782234B2 (enExample)
BR (1) BR0014433A (enExample)
CA (1) CA2385461C (enExample)
CZ (1) CZ300368B6 (enExample)
DE (1) DE60001510T2 (enExample)
DK (1) DK1216251T3 (enExample)
EA (1) EA004331B1 (enExample)
ES (1) ES2189768T3 (enExample)
HK (1) HK1044774B (enExample)
HU (1) HUP0202609A3 (enExample)
IL (2) IL148542A0 (enExample)
MX (1) MXPA02003243A (enExample)
NO (1) NO20021360L (enExample)
NZ (1) NZ517644A (enExample)
PL (1) PL200899B1 (enExample)
TW (1) TWI256395B (enExample)
WO (1) WO2001023395A2 (enExample)
ZA (1) ZA200201918B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
JP2007532650A (ja) 2004-04-14 2007-11-15 ワイス プロリンｃｃｉ−７７９（２，２−ビス（ヒドロキシメチル）プロピオン酸とのプロリン−ラパマイシン４２−エステル）ならびに細菌リパーゼを使用するプロリンｃｃｉ−７７９およびｃｃｉ−７７９の二段階酵素的合成
CN1942476A (zh) 2004-04-14 2007-04-04 惠氏公司 纳巴霉素42－酯衍生物的区位特异合成
CN1993368A (zh) 2004-08-10 2007-07-04 惠氏公司 Cci－779衍生物和其制备方法
RU2405566C9 (ru) 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
JP2008530090A (ja) 2005-02-09 2008-08-07 ワイス Ｃｃｉ−７７９多形及びその使用
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
EP2528906A2 (en) * 2010-01-28 2012-12-05 Fresenius Kabi Oncology Ltd Process for the preparation of temsirolimus and its intermediates
CN102020662B (zh) 2011-01-07 2013-02-13 天津市炜杰科技有限公司 一种驮瑞塞尔制备方法
MX2013011412A (es) * 2011-04-01 2014-04-30 Sandoz Ag Acilacion regioselectiva de rapamicina en la posicion c-42.
CN103421023B (zh) * 2013-07-30 2015-09-23 福建省微生物研究所 一种替西罗莫司的合成工艺
CN104086564B (zh) * 2014-07-30 2019-02-05 江苏奥赛康药业股份有限公司 一种高纯度坦罗莫司的制备方法
CN106146536B (zh) * 2015-04-25 2019-07-26 山东新时代药业有限公司 一种依维莫司的制备方法
CN109562187B (zh) * 2016-03-14 2022-05-17 威斯康星校友研究基金会 具有增强的抗癌功效的低聚乳酸缀合物和胶束
CN107561170B (zh) * 2016-07-02 2021-07-30 山东新时代药业有限公司 一种坦西莫司中间体的分析检测方法
CN108948045A (zh) * 2017-05-20 2018-12-07 鲁南制药集团股份有限公司 一种替西罗莫司的制备方法
CN108948046B (zh) * 2017-05-20 2020-11-10 鲁南制药集团股份有限公司 一种替西罗莫司的中间体及其制备方法
CN109206441B (zh) * 2017-06-30 2022-05-20 正大天晴药业集团股份有限公司 一种依维莫司的纯化方法
CN109776570A (zh) * 2017-11-14 2019-05-21 上海医药工业研究院 一种依维莫司中间体、其制备方法及其应用
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
CN109369679A (zh) * 2018-12-24 2019-02-22 江苏卓和药业有限公司 一种雷帕霉素的精制方法
CN109851626B (zh) * 2019-01-08 2021-11-02 扬子江药业集团四川海蓉药业有限公司 一种替西罗莫司的分离纯化方法
TW202134234A (zh) 2019-12-05 2021-09-16 美商奈維特製藥公司 雷帕黴素類似物及其用途
CN113372359A (zh) * 2020-03-10 2021-09-10 鲁南制药集团股份有限公司 一种坦西莫司的制备方法
CN114106014B (zh) * 2020-08-27 2024-03-15 鲁南制药集团股份有限公司 一种依维莫司的制备方法
CN115028658A (zh) * 2022-07-06 2022-09-09 国药集团川抗制药有限公司 雷帕霉素硅醇酯及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS97392A3 (en) * 1991-04-01 1992-12-16 American Home Prod Rapamycin silyl ethers
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS97392A3 (en) * 1991-04-01 1992-12-16 American Home Prod Rapamycin silyl ethers
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters

Also Published As

Publication number Publication date
KR20020029796A (ko) 2002-04-19
NO20021360D0 (no) 2002-03-19
JP2003510329A (ja) 2003-03-18
EA004331B1 (ru) 2004-04-29
CZ20021136A3 (cs) 2002-06-12
CN1176925C (zh) 2004-11-24
JP4289813B2 (ja) 2009-07-01
IL148542A (en) 2006-08-20
CA2385461A1 (en) 2001-04-05
AU7718200A (en) 2001-04-30
DK1216251T3 (da) 2003-06-16
EP1216251A2 (en) 2002-06-26
ZA200201918B (en) 2003-08-27
AU782234B2 (en) 2005-07-14
DE60001510T2 (de) 2003-10-02
HK1044774B (en) 2003-05-30
ES2189768T3 (es) 2003-07-16
CN1402731A (zh) 2003-03-12
IL148542A0 (en) 2002-09-12
EP1216251B1 (en) 2003-02-26
HK1044774A1 (en) 2002-11-01
WO2001023395A3 (en) 2001-10-25
HUP0202609A2 (hu) 2002-12-28
TWI256395B (en) 2006-06-11
ATE233269T1 (de) 2003-03-15
NO20021360L (no) 2002-03-19
BR0014433A (pt) 2002-06-11
DE60001510D1 (de) 2003-04-03
HUP0202609A3 (en) 2004-11-29
WO2001023395A2 (en) 2001-04-05
CA2385461C (en) 2009-03-17
KR100754236B1 (ko) 2007-09-03
MXPA02003243A (es) 2002-09-30
PL354461A1 (en) 2004-01-12
AR029181A1 (es) 2003-06-18
EA200200412A1 (ru) 2002-10-31
PL200899B1 (pl) 2009-02-27
NZ517644A (en) 2003-09-26

Similar Documents

Publication Publication Date Title
CZ300368B6 (cs) Zpusob výroby rapamycinového derivátu
US6277983B1 (en) Regioselective synthesis of rapamycin derivatives
US5120842A (en) Silyl ethers of rapamycin
EP1658295B1 (en) Regioselective synthesis of cci-779
JP5117390B2 (ja) メイタンシノールの調製法
CA2564811A1 (en) Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
WO1998009972A1 (en) Rapamycin derivatives with unnatural stereochemistries
SG186823A1 (en) Preparation of tesetaxel and related compounds and corresponding synthesis intermediate
HK1085482B (en) Regioselective synthesis of cci-779

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20100927